Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+0.56%+10.59%+58.13%+149.68% 1,257B
-1.18%-0.41%+43.69%+76.85% 651B
+0.04%+0.80%+36.20%+104.14% 510B
-1.56%-2.01%+50.67%+64.81% 388B
-2.53%+1.96%+75.29%+39.87% 366B
-0.02%+2.11%+32.16%+57.79% 303B
-0.72%+7.32%+11.29%+33.98% 288B
-0.52%+3.49%+56.46%+71.79% 252B
-0.80%+6.25%+38.49%+107.17% 211B
Average -0.63%+4.59%+44.71%+78.45% 469.63B
Weighted average by Cap. -0.46%+5.30%+47.92%+94.42%
Logo ElsaLys Biotech
ElsaLys Biotech specializes in the design and development of new-generation antibodies intended to modulate the immune systems of patients suffering from cancer or rare blood diseases. The company has a portfolio of 5 programs in the development phase, including LEUKOTAC® (Inolimomab), an immunotherapy antibody demonstrating a clinical benefit in Phase 3 of a rare disease with a very poor prognosis: acute steroid resistant reaction of the graft against the host.
Employees
-